comparemela.com
Home
Live Updates
Japan Grants Priority Review to Enfortumab Vedotin/Pembroliz
Japan Grants Priority Review to Enfortumab Vedotin/Pembroliz
Japan Grants Priority Review to Enfortumab Vedotin/Pembrolizumab in First-Line Urothelial Carcinoma
The sNDA for enfortumab vedotin-ejfv plus pembrolizumab in patients with metastatic urothelial cancer has received priority review in Japan.
Related Keywords
Japan ,
Madrid ,
Spain ,
United Kingdom ,
United States ,
Thomas Powles ,
Perez Valderrama ,
Ahsan Arozullah ,
University Of London ,
Astellas Pharma Inc ,
Japan Ministry Of Health ,
Barts Cancer Centre ,
Oncology Development At Astellas ,
Astellas Pharma ,
Oncology Development ,
Medicinal Products ,
Human Use ,
European Medicines ,
Enfortumab Vedotin Ejfv Padcev ,
Pembrolizumab ,
Japans Ministry Of Health ,
Labour ,
End Welfare ,
Phase 3 Ev 302 Keynote A39 Trial Nct04223856 ,